Search research articles
Contact Us
Filters
Showing results (131-140 of 174) with videos related to
Page
of 18
Sort By:
Blood
|
December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.
The Lancet. Oncology
|
December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood
|
December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Lancet (London, England)
|
December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Blood Cancer Journal
|
June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
American Journal of Hematology
|
June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)
Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
Current Medical Research and Opinion
|
July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
Giuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 174) with videos related to
Sort By:
Page
of 18
Blood
|
December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.
The Lancet. Oncology
|
December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood
|
December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Lancet (London, England)
|
December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Blood Cancer Journal
|
June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
American Journal of Hematology
|
June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)
Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
Current Medical Research and Opinion
|
July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
Giuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Page
of 18